Business Context and Reporting Period
Company: Lucid Diagnostics Inc. (LUCD)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Lucid is a commercial-stage cancer prevention diagnostics company focused on detecting esophageal adenocarcinoma (EAC) precursors in patients with gastroesophageal reflux disease (GERD). Its flagship product is the EsoGuard Esophageal DNA Test, performed on samples collected via the EsoCheck device. The company operates as a single segment and is currently an Emerging Growth Company (EGC) and Smaller Reporting Company.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $4,706 | $4,346 |
| Cost of Revenue | $6,670 | $7,099 |
| Gross Profit (Loss) | $(1,964) | $(2,753) |
| Operating Loss | $(49,640) | $(46,052) |
| Net Loss | $(58,010) | $(45,529) |
| Net Loss Attributable to Common Stockholders | $(70,569) | $(53,025) |
| Cash and Cash Equivalents (Year End) | $34,705 | $22,358 |
| Net Cash Used in Operating Activities | $(46,485) | $(44,140) |
| Net Cash Provided by Financing Activities | $59,029 | $48,248 |
| Senior Secured Convertible Notes (Fair Value) | $24,000 | $18,600 |
Note: The company reported a negative gross margin in both periods due to high fixed costs relative to low test volumes.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by approximately 8.3% ($0.4 million) year-over-year, driven by increased consideration received for EsoGuard tests.
- Expense Increases:
- General & Administrative (G&A): Increased by $3.7 million (18.4%), primarily due to an amended Management Services Agreement (MSA) with PAVmed ($1.8 million) and higher professional fees related to financing ($1.6 million).
- Sales & Marketing: Increased by $1.2 million (7.3%) due to higher compensation and third-party consulting costs.
- Non-Operating Items: The 2025 period included a $7.7 million expense related to the change in fair value of the 2024 Convertible Notes. In contrast, 2024 included a $5.2 million loss on debt extinguishment.
- Capital Structure: The company raised significant capital in 2025 through multiple equity offerings (March, April, and September) and an ATM facility, resulting in a net increase in cash on hand from $22.4 million to $34.7 million.
Guidance, Outlook, Risks, and Contingencies
Going Concern Warning
The independent auditors have issued an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern. Management plans to address this through additional equity/debt financings and revenue growth, but there is no assurance these plans will be successful.
Reimbursement and Regulatory Outlook
- Medicare Coverage: The company submitted a clinical evidence package in November 2024 to request reconsideration of the Local Coverage Determination (LCD) non-coverage language. A Contractor Advisory Committee (CAC) meeting was held in September 2025 to discuss the evidence. A final decision is pending.
- Commercial Coverage: Highmark Blue Cross Blue Shield issued a positive coverage policy for New York state effective May 2025. The company continues to pursue commercial insurer coverage.
- VA Contract: In January 2026, the company announced a contract with the U.S. Department of Veterans Affairs to provide EsoGuard testing nationwide.
- Regulatory Status: EsoGuard is currently marketed as a Laboratory Developed Test (LDT). The FDA rescinded its 2024 rule regarding LDT regulation in September 2025, reverting to pre-2024 language.
Key Risks
- Liquidity: Recurring losses and negative operating cash flows require continuous capital raising, leading to significant dilution.
- Reimbursement Uncertainty: Commercial success is heavily dependent on securing Medicare and private payer coverage, which remains uncertain.
- PAVmed Relationship: The company relies on PAVmed for management services (MSA fees increased to $1.05 million/month in 2025, with a one-time increase in December). PAVmed holds approximately 27.5% of voting stock and has significant influence.
- Dilution: Significant convertible debt ($21.975 million principal) and preferred stock (Series B and B-1) are outstanding, with conversion features that could substantially increase share count.
Investor Verification Checklist
- Medicare LCD Status: Verify the outcome of the MolDx reconsideration process and the final Medicare coverage decision for EsoGuard.
- Cash Runway: Assess the sufficiency of the $34.7 million cash balance against the $46.5 million annual operating cash burn and upcoming debt obligations.
- Debt Covenants: Review compliance with the 2024 Convertible Notes covenants, specifically the requirement to maintain $5.0 million in available cash.
- PAVmed MSA Terms: Confirm the long-term sustainability of the management services fees and the potential for further increases or stock-settlement dilution.
- Commercial Adoption: Monitor the volume of tests performed and the rate of commercial insurance approvals beyond the initial Highmark policy.